NCT03710616

Brief Summary

The real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
700

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 24, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 10, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 18, 2018

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

August 1, 2019

Status Verified

July 1, 2019

Enrollment Period

4.8 years

First QC Date

July 10, 2018

Last Update Submit

July 31, 2019

Conditions

Non-small Cell Lung Cancer

Keywords

early-stage NSCLC, real-world evidences, patient survivals

Outcome Measures

Primary Outcomes (1)

  • Disease-free survival rates within the configured observation periods

    Disease-free survival rates within 3-month, 6-month, 1-year, 2-year, and 3-year observation periods;

    2009-2017

Secondary Outcomes (1)

  • Disease-free survival rates at the configured locations and observation periods

    2009-2017

Other Outcomes (3)

  • Impact factors of disease-free survival rates

    2009-2017

  • Overall rates

    2009-2017

  • Rates of perioperative complications

    2009-2017

Interventions

SurgeriesPROCEDURE

Surgical operations plus systematic lymphadenectomies

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pathologically diagnosed early-stage (I-IIIA) NSCLC patients who were operated with radical operations of the lung cancer

You may qualify if:

  • The patients who were operated with radical operations of the lung cancer;
  • The patients with clinical I-IIIA staging tumors;
  • The pathologically diagnosed NSCLC patients;

You may not qualify if:

  • \- Not be specified;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangzhou, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Wenhua LIANG, Ph.D

    The First Affiliated Hospital of Guangzhou Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jianxing HE, MD

CONTACT

0086-20-83062114hejx@vip.163.com

Wenhua LIANG, Ph.D

CONTACT

0086-20-83062114liangwh1987@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 10, 2018

First Posted

October 18, 2018

Study Start

March 24, 2018

Primary Completion

December 30, 2022

Study Completion

January 1, 2023

Last Updated

August 1, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)